Black Rock Inc. Sigilon Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $1.38 $4,451 - $18,066	-13,092 Reduced 1.23%	1,049,169 $975,000
Q4 2022 Feb 13, 2023	BUY	$0.29 - $0.69 $315 - $750	1,088 Added 0.1%	1,062,261 $371,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $2,361 - $4,230	-4,919 Reduced 0.46%	1,061,173 $535,000
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $479,273 - $1.06 Million	-647,667 Reduced 37.79%	1,066,092 $885,000
Q1 2022 May 12, 2022	SELL	$1.24 - $3.03 $28,269 - $69,077	-22,798 Reduced 1.31%	1,713,759 $2.52 Million
Q4 2021 Feb 10, 2022	SELL	$2.58 - $6.13 $11,313 - $26,880	-4,385 Reduced 0.25%	1,736,557 $4.79 Million
Q3 2021 Nov 09, 2021	BUY	$4.42 - $10.61 $1.49 Million - $3.57 Million	336,658 Added 23.97%	1,740,942 $9.84 Million
Q2 2021 Aug 11, 2021	BUY	$9.15 - $20.17 $12.8 Million - $28.3 Million	1,404,284 New	1,404,284 $15.1 Million

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.